153 related articles for article (PubMed ID: 20833478)
21. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
22. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
23. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
Mokhtari D; Welsh N
Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
[TBL] [Abstract][Full Text] [Related]
24. Imatinib as a paradigm of targeted therapies.
Druker BJ
Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
[TBL] [Abstract][Full Text] [Related]
25. Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.
Fujita KI; Ishida H; Kubota Y; Sasaki Y
Curr Drug Metab; 2017; 18(3):186-198. PubMed ID: 28059038
[TBL] [Abstract][Full Text] [Related]
26. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
Drenberg CD; Baker SD; Sparreboom A
Clin Pharmacol Ther; 2013 Mar; 93(3):215-9. PubMed ID: 23419484
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
28. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
29. [Historical aspect of molecular-targeted therapy for cancer].
Sone S; Otsuka K; Tobiume M; Tada H
Nihon Rinsho; 2010 Oct; 68(10):1787-95. PubMed ID: 20954319
[TBL] [Abstract][Full Text] [Related]
30. Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies.
Ng T; Chan A
Crit Rev Oncol Hematol; 2012 Jan; 81(1):58-74. PubMed ID: 21429761
[TBL] [Abstract][Full Text] [Related]
31. How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.
Ward MB; Reuter SE; Martin JH
Clin Pharmacokinet; 2016 Oct; 55(10):1171-1177. PubMed ID: 27085335
[TBL] [Abstract][Full Text] [Related]
32. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.
Liu S; Kurzrock R
Cancer Treat Rev; 2014 Aug; 40(7):883-91. PubMed ID: 24867380
[TBL] [Abstract][Full Text] [Related]
33. Practical guidelines for dose individualization of anticancer targeted drugs.
Sáez MI; Quero C; Trigo JM; Muros B; Alba E
Clin Transl Oncol; 2012 Nov; 14(11):812-9. PubMed ID: 23065600
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy in pediatric and adolescent oncology.
Bernstein ML
Cancer; 2011 May; 117(10 Suppl):2268-74. PubMed ID: 21523745
[TBL] [Abstract][Full Text] [Related]
35. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.
Noda S; Morita SY; Terada T
Biol Pharm Bull; 2022; 45(7):814-823. PubMed ID: 35786588
[TBL] [Abstract][Full Text] [Related]
36. [Role of individualized dosing in oncology: are we there yet?].
Joerger M
Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?
Ornstein MC; Rini BI
Clin Cancer Res; 2016 Dec; 22(23):5626-5628. PubMed ID: 27663599
[TBL] [Abstract][Full Text] [Related]
38. Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition.
Gallo JM
Clin Pharmacol Ther; 2013 Mar; 93(3):236-8. PubMed ID: 23340476
[No Abstract] [Full Text] [Related]
39. Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5-fluorouracil and tyrosine kinase inhibitors.
Martin JH; Galettis P; Flynn A; Schneider J
Pharmacol Res Perspect; 2024 Apr; 12(2):e1182. PubMed ID: 38429945
[TBL] [Abstract][Full Text] [Related]
40. Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?
Kollipara S; Chougule M; Boddu R; Bhatia A; Ahmed T
AAPS J; 2024 Jun; 26(4):66. PubMed ID: 38862853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
